AgomAb Therapeutics N.V. announced today the closing of a $74 Million Series B financing round, led by Redmile Group with participation from Cormorant Capital and existing investors Pontifax, Andera Partners, Omnes Capital, Advent France Biotechnology and V-Bio Ventures.
AgomAb Therapeutics N.V. (‘AgomAb’), a privately held Belgian biotherapeutics company developing agonistic antibodies for the regeneration of damaged tissues, announces today that it has secured additional financing in an extension to its Series A financing round from new investor Andera Partners.
AgomAb Therapeutics N.V., a privately held Belgian biotherapeutics company developing agonistic antibodies for regeneration of damaged tissues, announces today that it has secured €21m in a Series A financing round from a strong international investor syndicate.
End of content
No more pages to load
Looking to connect with us?
June 10-18, 2021
Kempen Life Sciences Crossover Conference
June 16, 2021
J.P. Morgan European Healthcare Conference
June 17, 2021
Belfius Kepler Cheuvreux Belgian Life Science Day
June 22, 2021
Solebury Trout & Venrock’s 5th Annual EU Investor Tour
July 13, 2021
LifeSci Advisors – Annual Private Summer Symposium
July 21-23, 2021
Knowledge for Growth
September 27-29, 2021
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.